13 results about "Drug assay" patented technology

This invention provides a method for constructing and applying a fingerprint spectrum of Chushi Weiling Decoction, belonging to the field of drug detection technology. The method involves first preparing a test solution using Chushi Weiling Decoction, then using acetonitrile (A)-0.18~0.22wt% formic acid aqueous solution as the mobile phase, and obtaining the fingerprint spectrum of Chushi Weiling Decoction through high-performance liquid chromatography (HPLC). A standard fingerprint spectrum is then established using the "Similarity Evaluation System for Chromatographic Fingerprint Spectrum of Traditional Chinese Medicine" for quality evaluation or control throughout the research, development, production, and clinical application of Chushi Weiling Decoction. This invention's method for constructing the fingerprint spectrum of Chushi Weiling Decoction enables the detection of the main medicinal components in Chushi Weiling Decoction solely through HPLC, thus providing a more comprehensive reflection of the quality status of Chushi Weiling Decoction.

The application provides a construction method and a content determination method of a synovitis preparation characteristic spectrum, and belongs to the technical field of drug detection. The construction method is that a test sample solution is prepared by using the synovitis preparation, then acetonitrile-0.08-0.12wt% formic acid aqueous solution is used as a mobile phase, high performance liquid chromatography detection is carried out, the characteristic spectrum of the synovitis preparation is obtained, and the content of components in the synovitis preparation is further determined. The method can comprehensively cover the key active components of core medicinal materials in the prescription of the synovitis preparation, realizes the synchronous detection of multiple categories and multiple target components, and completely solves the defects of single quality control index and incomplete coverage in the prior art.

The present application relates to the technical field of drug detection, in particular to a method for determining the content of six components in Shengmai Yin soft capsules based on one measurement multiple evaluation. The method uses schisandrol A as an internal standard for one measurement multiple evaluation, establishes the relative correction factors of schisandrol B, angeloylgomisin H, schisantherin A, schisantherin B and schisantherin C, and calculates the content of the above components in Shengmai Yin soft capsules (Dangshen Fang) through the relative correction factors. The specific steps include: preparation of test sample solution; preparation of reference sample solution; chromatographic conditions and system suitability test; determination and calculation. The present application overcomes the single and one-sidedness of the quality control of Shengmai Yin soft capsules (Dangshen Fang), and has important significance for further improving the drug quality control standard and ensuring the clinical efficacy of drugs.

A fully automatic medicine testing instrument and an automatic testing method are provided. The fully automatic medicine testing instrument includes an outer housing. A shaking mechanism, a heating mechanism, a reagent reservoir configured to store test samples and test reagents, an optical detection mechanism configured to test absorbance of test samples, a moving mechanism configured to move microplate and pipettes, a pipette holder, and a microplate holder configured to hold microplate for treating test samples are arranged inside the outer housing. The reagent reservoir is located in middle of bottom of the outer housing, the pipette holder and the microplate holder are respectively located on two sides of the reagent reservoir, the optical detection mechanism and the shaking mechanism are respectively located on the other two sides of the reagent reservoir, and the heating mechanism is located on one side, close to the microplate holder, of the shaking mechanism.

The present invention relates to devices and methods for detecting date rape drugs (DRDs) in beverages during social events. The device includes a cellphone, and further includes one or more protective covers, screen cover, stylus, or other add-ons, either individually or in combination. The device incorporates a user-friendly DRD detection system physically attached or integrated with the cellphone or any one of its accessories, ensuring uninterrupted use of the device's primary functions, wherein this physical attachment and / or integration minimizes the likelihood of users forgetting the device elsewhere and / or removing the DRD detection system, thus ensuring its immediate availability when needed. The DRD detection system's operation does not significantly impact the regular use of the cellphone or its accessories, maintaining convenience and safety in social settings.

This invention belongs to the field of drug detection technology, and relates to a platinum-iridium bimetallic nanozyme, its preparation method, and its application in immunochromatographic detection. The method includes: first, preparing a bimetallic nanozyme with a platinum core and an iridium shell; then, conjugating it with an antibody to create a colorimetric enhanced immunolabel. Based on this, a competitive immunochromatographic test strip is constructed, with the corresponding drug antigen immobilized on the T line and a quality control capture agent immobilized on the C line. During detection, the sample and label are mixed and added dropwise. If the sample does not contain the target drug, the labeled antibody binds to the antigen on the T line, resulting in color development; if the target drug is present, it competes with the T line for binding to the labeled antibody, leading to a weakening of the T line signal. A colorimetric solution is added, utilizing the catalytic activity of the nanozyme to amplify the signal, significantly improving sensitivity. This invention achieves detection limits of 0.41 ng / mL for vancomycin and 0.12 ng / mL for chlorpheniramine maleate, exhibiting advantages such as speed, high sensitivity, and ease of operation, making it suitable for therapeutic drug monitoring and trace drug residue detection.

The present invention relates to a composition for detecting an opioid-based drug, the composition comprising an opioid receptor nanodisc. Specifically, the opioid receptor nanodisc according to the present invention detetcs an opioid-based drug with high sensitivity and selectivity, and thus may find useful application in diagnosing opioid-based drug addiction or detecting an opioid-based drug.

The present application relates to the technical field of microneedle transdermal drug delivery, and in particular to a microneedle system with self-adaptive penetration depth. The microneedle system comprises: a microneedle array for penetrating the skin, providing a sampling point for detecting the skin impedance at the skin layer touched by the needle tip, and releasing drugs; a detection unit connected with the microneedle array, configured to obtain the skin impedance at the sampling point in a short pulse mode, and output a control signal when judging that the needle tip of the microneedle array has penetrated the stratum corneum according to the skin impedance; and an execution unit connected with the microneedle array and the detection unit respectively, configured to receive the control signal from the detection unit to stop the microneedle array from continuing to penetrate the skin after the detection unit determines the penetration. In this way, the microneedle penetration depth can be actively limited based on the change in the electrical properties of the skin during the microneedle penetration process, effectively addressing the problem of individual differences in the skin, and the system has the active identification ability and automatic adjustment ability of the real-time penetration state.

A method for electronically tracking and verifying the application, removal, and chain of custody of wearable drug testing patches is provided. The method involves applying a drug testing patch to a wearer, electronically logging application events associated with the drug patch, including capturing electronic signatures from both the wearer and a first technician, and compiling an application chain of custody document for the respective drug patch that links client information, case record information, the patch serial number, and the respective electronic signature identifiers. After a predetermined wear duration, the drug patch is removed by a second technician, and a patch removal event is logged, including capturing electronic signatures from both the wearer and the second technician. A completed chain of custody document, including a barcode linked to the client, case record, and the patch is generated to allow a laboratory to upload results of an associated testing protocol.

This invention belongs to the field of drug detection technology, specifically relating to a method for detecting O-nordrod and its related substances using HPLC. The test solution, blank solution, reference solution, and impurity reference solution are injected into the HPLC instrument, and the chromatograms are recorded. The content of O-nordrod and its related substances in the test solution is calculated using the peak area normalization method. The related substances include one or more of impurities A, B, C, D, or E. This invention exhibits good specificity, robustness, and stability, as well as excellent precision and accuracy.

This invention provides a method for determining impurities in ipratropium bromide inhalation solution, belonging to the field of pharmaceutical detection technology. The method involves preparing a test solution from the ipratropium bromide solution, using a mixture of ammonium acetate buffer and acetonitrile as mobile phase A and an acetonitrile mixture as mobile phase B, followed by isocratic elution at a volume ratio of 30:70 and high-performance liquid chromatography (HPLC) to detect impurities sulfur and butylated hydroxytoluene (BHT) in the ipratropium bromide solution. This invention employs HPLC, resulting in more accurate and consistent results with theoretical predictions. Furthermore, the method exhibits satisfactory recovery and specificity, high accuracy, and high precision. It provides a novel and accurate method for determining sulfur (S) and BHT in ipratropium bromide inhalation solution, enabling better quality control and evaluation of ipratropium bromide inhalation solutions.